IN THE CLAIMS:

Kindly amend Claims 1, 3, 5, 8, 9 and 14 as follows:

1. (currently amended) A monocyclic compound having the formula (1):



in which:

X_1, X_2, X_3, X_4, which may be the same or different from one another, is selected from the group consisting of -CONR-, -NRCO-, -OCO-, -COO-, $-CH_2NR-$ and $-NR-CH_2-$, where R is H or a C_{1-3} alkyl or benzyl;

f, g, h, m, which may be the same or different from one another, may be 0 or 1;

R_1 and R_2 which may be the same or different from one another, represent the side chain of a natural amino acid selected from the group consisting of tryptophan, phenylalanine, tyrosine and histidine, or the side chain

of a non-natural amino acid selected from the group consisting of:

tryptophan and phenylalanine, either mono- or di-substituted with residues selected from the group consisting of C_{1-3} alkyl or halo-alkyl, C_{1-3} alkoxyl or amino-alkoxyl, halogen, OH, NH_2 and $NR_{13}R_{14}$, where R_{13} and R_{14}, which may be the same or different from one another, represent a hydrogen or C_{1-3} alkyl group;

R_3 is selected from the group consisting of:

- linear or branched alkyl having the formula C_nH_{2n+1} with n=1-5 (selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl and t-butyl) cycloalkyl or alkylcycloalkyl of formula C_nH_{2n-1} with n=5-9 (selected from the group consisting of: cyclopentyl, cyclohexyl and methylcyclohexyl)

$-(CH_2)_r-Ar_1$, where r=1 or 2 and where Ar_1 is an aromatic group selected from the group consisting of: α-naphthyl, β-naphthyl, phenyl, indole, said Ar_1 group being possibly substituted with a maximum of two residues selected from the group consisting of: C_{1-3} alkyl, CF_3, C_{1-3} alkoxyl, Cl, F, OH and NH_2;

R_4 represents an L-Q group where:

L is a chemical bond ~~of~~ or CH_2, and

Q is selected from the group consisting of:

- OH, NH_2, NR_9R_{10}, OR_{11}, and where R_9 and R_{10}, which may be the same or different from one another, represent a hydrogen or C_{1-3}alkyl group, C_{1-3}hydroxy alkyl, C_{1-3}dihydroxyaklyl, C_{1-3}alkyl-$CONHR_{12}$ (wherein R_{12} is a monoglycosidic group derived from D or L pentoses or hexoses (selected from the group consisting of ribose, arabinose, glucose, galactose, fructose, glucosamine, galactosamine N-acetylglucosamine and

N-acetylgalactosamine)), C_{1-3}alkyltetrazole, C_{1-3}alkyl-COOH or wherein R_9R_{10} are joined together to form with the N atom a morpholine or a piperidine ring and where R_{11} is a C_{1-3} alkyl chain, or a C_{2-4} amino-alkyl chain;
$NHCOR_8$ wherein R_8 is a cyclohexane containing from 2 to 4 OH groups, C_{1-6} alkyl chain containing a polar group (chosen in the group consisting of NH_2, COOH, $CONHR_{12}$, (wherein R_{12} is as hereabove defined) or [1,4']bipiperidine))
- COOH, $COOR_{17}$ or $CONHR_{12}$, wherein R_{12} is as hereabove defined and R_{17} is as R_{12} or a group 4-nitrobenzyl
- R_5, R_6, R_7 are [[H_2]] H in which the carbon atom that carries the substituents R_3 and R_7 has configuration R;
wherein when R_1=R_2= a side chain of ~~trytophan~~ tryptophan and R_4= CH_2OH then R_3 is not isopropyl.

2. (canceled)

3. (previously amended) A compound according to Claim 1 selected from:

(a) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH($CH_2C_6H_5$)-CH_2-NH]}
(b) Cyclo{-Suc-Trp-Phe-[(S)-NH-CH($CH_2C_6H_5$)-CH_2-NH]}
(c) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH($CH_2C_6H_{11}$)-CH_2-NH]}
(d) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH($CH_2C_6H_4$(4-OCH_3))-CH_2-NH]}
(e) Cyclo{-Suc-Trp(5F)-Phe-[(R)- NH-CH($CH_2C_6H_5$)-CH_2-NH]}
(f) Cyclo{-Suc-Trp(Me)-Phe-[(R)- NH-CH($CH_2C_6H_5$)-CH_2-NH]}
(g) Cyclo{-Suc-Phe(3,4-Cl)-Phe-[(R)- NH-CH($CH_2C_6H_5$)-CH_2-NH]}
(h) Cyclo{-Suc-Trp-Phe(3,4-Cl)-[(R)- NH-CH($CH_2C_6H_5$)-CH_2-NH]}
(i) Cyclo{-Suc-Trp-Tyr-[(R)-NH-CH($CH_2C_6H_5$)-CH_2-NH]}
(j) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH($CH_2C_6H_3$-3,4-diCl)-CH_2-NH]}
(k) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH($CH_2C_6H_4$-4-OH)-CH_2-NH]}
(l) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH(CH_2-CH_2-C_6H_5)-CH_2-NH]}
(m) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH(CH_2-2-napthyl)-CH_2-NH]}
(n) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH(CH_2-indol-3-yl)-CH_2-NH]}

(o) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH(CH_2-5-F-indol-3-yl)-CH_2-NH]}

(p) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_4-3-F)-CH_2-NH]}

(q) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_3-3,4-diF-CH_2-NH]-}

(r) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_4-4-CF_3-CH_2-NH]-}

(s) Cyclo{-Suc-Trp-Phe-[(R)-NH-CH_2-CH($CH_2C_6H_5$)-NH]}

(t) Cyclo{-Suc-Trp-Phe-[(S)-NH- CH_2-CH($CH_2C_6H_5$)-NH]}

(u) Cyclo{-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2-NH]-$(CH_2)_3$CO-}

(v) Cyclo{-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2-N(CH_3)]-$(CH_2)_3$CO-}

(w) Cyclo{-Suc[1(S)-NH_2]-Trp-Phe-[(R)NH-CH(CH_2-C_6H_5)-CH_2NH]-}

(x) Cyclo{-Suc[1(R)-NH_2]-Trp-Phe-[(R)NH-CH(CH_2-C_6H_5)-CH_2NH]-}

(y) Cyclo{-Suc[2(S)-NH_2]-Trp-Phe-[(R)NH-CH(CH_2-C_6H_5)-CH_2NH]-}

(z) Cyclo{-Suc[2(R)-NH_2]-Trp-Phe-[(R)NH-CH(CH_2-C_6H_5)-CH_2NH]-}

(aa) Cyclo{-Suc[1(S)-NH(CH_3)]-Trp-Phe-[(R)NH-CH(CH_2-C_6H_5)-CH_2NH]-}

(ab) Cyclo{-Suc[1-COO(CH_2-C_6H_4-4-NO_2)]-Trp-Phe-[(R)NH-CH(CH_2-C_6H_5)-CH_2NH]-}

(ac) Cyclo{-Suc(1-COOH)-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2-NH]}

[Cyclo{-Suc(1-COOH)-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2-NH]}]

(ad) Cyclo{-Suc(1-OH)-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2-NH]}

(ae) Cyclo{-Suc(2-COOH)-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2-NH]}

(af) Cyclo{-Suc(2-OH)-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2-NH]}

(ag) Cyclo{-Suc[1(S)-(2H-tetrazolyl-5-ylmethyl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2-NH]-} trifluoroacetic acid

(ah) Cyclo{-Suc[1(S)-(morpholin-4-yl)]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2-NH]-} trifluoroacetic acid

(ai) Cyclo{-Suc[1(S)-$N(CH_3)_2$]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2-NH]-} trifluoroacetic acid

(aj) Cyclo{-Suc[1(S)-(piperidin-4-yl]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2-NH]-} trifluoroacetic acid

(ak) Cyclo{-Suc[1(S)-($N(CH_2CH_2OH)_2$)]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2-NH]} trifluoroacetic acid

(al) Cyclo{-Suc[1(S)-($N(CH_2CH(OH)CH_2OH)$]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2-NH]-} trifluoroacetic acid

(am) Cyclo{-Suc[1(S)-(3-carboxypropanoyl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2-NH]-}

(an) Cyclo{-Suc[1(S)-[3-N'-ß-D-glucopyranos-1-yl)-carboxamidopropanoyl]amino]-Trp-Phe-[(R)NH-CH(CH_2-C_6H_5)-CH_2NH]-}

(ao) Cyclo{-Suc[1(S)-[(carboxymethyl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2-NH]-} trifluoroacetic acid

(ap) Cyclo{-Suc[1(S)-[N'-ß-D-glucopyranos-1-yl)-carboxyamideomethyl]amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2-NH]-} trifluoroacetic acid

(aq) Cyclo{-Suc[1(S)-(quinyl)amine]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2-NH]-}

(ar) Cyclo{-Suc[1(S)-(4-aminobutanoyl)amino]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2-NH]-} trifluoroacetic acid

(as) Cyclo{-Suc[1(S)-[1,4')bipiperidin-1-yl]acetamido]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2-NH]-} trifluoroacetic acid

(at) Cyclo{-Suc[1-N-(ß-D-glucopyranos-1-yl)-carboxyamido]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2-NH]-}

(au) Cyclo{-Suc[1(S)-[N'-(2-N-acetyl-ß-D-glucopyranos-1-yl)-carboxyamido]-Trp-Phe-[(R)-NH-CH(CH_2-C_6H_5)-CH_2-NH]-}.

4. (canceled)

5. (previously amended) A composition comprising a compound of formula (I) according to Claim 1 in combination with a suitable carrier or excipient.

6. (currently amended) ~~Pharmaceutical~~ [[c]]Compositions according to Claim 5, to be used as tachykinin antagonists.

7. (currently amended) ~~Pharmaceutical~~ [[c]]Compositions according to Claim 6, to be used asantagonists of the human NK-2 receptor.

8. (canceled)

9. (canceled)

10. (canceled)

11. (previously amended) A method of inhibiting bronchoconstriction comprising administering a compound according to Claim 1 for a time and under conditions effective to antagonize NK-2 (neurokinin-2) receptors.

12. (previously amended) A method of inhibiting bronchoconstriction comprising administering a compound according to Claim 1 to a mammal afflicted with asthma for a time and under conditions effective to antagonize NK-2 receptors.

13. (previously amended) A method of inhibiting bronchoconstriction comprising administering a compound according to Claim 1 to a mammal afflicted with an anxiety

disorder for a time and under conditions effective to antagonize NK-2 receptors.

14. (currently amended) A method of inhibiting bronchoconstriction comprising administering quantities of between 0.02 and 10 mg/kg of body weight of active principle consisting of a compound ~~of formula (I),~~ according to Claim 1, to a patient afflicted with asthma, coughing, pulmonary irritation, intestinal spasms, spasms of the biliary tract, local spasms of the bladder and of the ~~uterer~~ ureter during cystitis[[, and]] or kidney infections and colics for a time and under conditions effective to antagonize NK-2 receptors.

15. (original) A mixture comprising two or more compounds according to claim 1.

16. (original) A method of inhibiting bronchoconstriction comprising administering a compound according to claim 1 for a time and under conditions effective to antagonize NK-2 receptors.

17. (original) A method of inhibiting bronchoconstriction comprising administering a compound according to claim 1 to a mammal in need thereof for a time and under conditions effective to antagonize NK-2 receptors.

18. (original) A method according to claim 17 wherein said mammal is afflicted with a disorder selected from the group consisting of the bronchospastic and inflammatory component of asthma, coughing, pulmonary irritation, intestinal spasms, spasms of the biliary tract, local